Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation.

Abhinav VasudevanZaid S ArdalanNavera AhmedRoss ApostolovPaul J GowAdam G TestroEd J GanePeter W Angus

Published in: JGH open : an open access journal of gastroenterology and hepatology (2018)

Substitution of HBIg with TDF in patients on LAM is well tolerated and effective for the long-term prevention of HBV recurrence posttransplantation. Renal dysfunction occurs frequently in the posttransplant setting and can require dose adjustment of TDF or change of therapy.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
hepatitis b virus
prognostic factors
oxidative stress
peritoneal dialysis
stem cells
patient reported outcomes